-

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

No Shareholder Action Required at This Time

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.

Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Sage Board of Directors will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.

There is no guarantee that any transaction will result from Biogen’s proposal. Sage’s shareholders do not need to take any action at this time.

About Sage Therapeutics

Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on Facebook, LinkedIn, Instagram, and X.

Contacts

Investor Contact
Ashley Kaplowitz
Ashley.Kaplowitz@sagerx.com

Media Contacts
Francesca Dellelci
Francesca.Dellelci@sagerx.com

Tim Lynch / Jed Repko
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

Sage Therapeutics, Inc.

NASDAQ:SAGE

Release Versions

Contacts

Investor Contact
Ashley Kaplowitz
Ashley.Kaplowitz@sagerx.com

Media Contacts
Francesca Dellelci
Francesca.Dellelci@sagerx.com

Tim Lynch / Jed Repko
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

More News From Sage Therapeutics, Inc.

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. “We delivered strong growth in revenue and shipments of ZURZUVAE during the first quarter of 2025 through the team’s disciplined execution and unwavering commitment to bringing ZURZUVAE to more women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “We remain focused on establi...

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 2025 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeu...

Sage Therapeutics Announces R&D Leadership Transition

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company’s product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on...
Back to Newsroom